Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
Own experience of using anti-HER2 therapy for cancer of the intrahepatic cholangiocarcinoma
P. V. Golubev,
E. S. Kuzmina,
I. A. Pokataev,
S. A. Golubeva,
D. S. Kontorovich,
R. S. Sydykova,
S. A. Parts,
V. N. Galkin https://doi.org/10.33667/2078-5631-2024-32-14-18
Abstract
Cancer of the biliary tract is rare and one of the most aggressive malignancies. The main method of radical treatment is surgical. However, only 1/3 of patients can use this approach, while the rest of the patients have an unresectable, locally widespread or already metastatic process. The therapeutic tactic of this group of patients is systemic drug antitumor therapy. In this article, we present a description of a clinical case of effective treatment of a patient with advanced intrahepatic cholangiocarcinoma using not only standard cytostatics, but also modern targeted drugs.
About the Authors
P. V. Golubev
Moscow City Hospital named after S.S. Yudin
Russian Federation
Russian Federation
Golubev Pavel V., PhD Med, oncologist at Chemotherapy Dept No 2, Oncology Center No 1
Moscow
E. S. Kuzmina
Moscow City Hospital named after S.S. Yudin
Russian Federation
Russian Federation
Kuzmina Evgeniya S., head of Chemotherapy Dept No 2, Oncology Center No 1
Moscow
I. A. Pokataev
Moscow City Hospital named after S.S. Yudin
Russian Federation
Russian Federation
Pokataev Ilya A., DM Sci (habil.), head of Chemotherapy Treatment Service, Oncology Center No 1
Moscow
S. A. Golubeva
P.A. Herzen Moscow Oncology Research Institute – Branch of National Medical Radiology Research Center
Russian Federation
Russian Federation
Golubeva Sofia A., oncologist at Combined Treatment Dept No 1
Moscow
D. S. Kontorovich
Moscow City Hospital named after S.S. Yudin
Russian Federation
Russian Federation
Kontorovich Daria S., radiologist at Dept of Radiation Diagnostics, Oncology Center No 1
Moscow
R. S. Sydykova
Moscow City Hospital named after S.S. Yudin
Russian Federation
Russian Federation
Sydykova Rozana S., oncologist at Chemotherapy Dept No 2, Oncology Center No 1
Moscow
S. A. Parts
Moscow City Hospital named after S.S. Yudin
Russian Federation
Russian Federation
Parts Sergey A., PhD Med, deputy chief physician for Oncology
Moscow
V. N. Galkin
Moscow City Hospital named after S.S. Yudin
Russian Federation
Russian Federation
Galkin Vsevolod N., DM Sci (habil.), professor, chief physician
Moscow
References
1. Buettner S., van Vugt J.L., Ijzermans J.N., Groot Koerkamp B. Intrahepatic cholangiocarcinoma: currentperspectives. OncoTargetsTher. 2017; 10: 1131–1142. DOI: 10.2147/OTT.S93629.
2. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40(3):472–477.https://doi.org/10.1016/j.jhep.2003.11.030
3. Khan SA, Emadossadaty S, Ladep NG, Thomas HC, Elliott P, Taylor-Robinson SD et al. Rising trends in cholangiocarcinoma: is the ICD classifi cation system misleading us? J Hepatol. 2012;56(4):848–854.https://doi.org/10.1016/j.jhep.2011.11.015
4. Shin HR, Oh JK, Lim MK, Shin A, Kong HJ, Jung KW et al. Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J Korean Med Sci. 2010;25(7):1011–1016. https://doi.org/10.3346/jkms.2010.25.7.1011
5. Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E, Vecchia CL. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol. 2013;24(6):1667–1674. https://doi.org/10.1093/annonc/mds652
6. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54(1):173–184. https://doi.org/10.1002/hep.24351
7. Buettner S., van Vugt J.L., Ijzermans J.N., Groot Koerkamp B. Intrahepatic cholangiocarcinoma: current perspectives. OncoTargetsTher. 2017; 10: 1131–1142. DOI: 10.2147/OTT.S93629.
8. Gurmikov BN, Kovalenko IA, Paichadze AA, Marinova LA, Gritskevich AA, Zhao AV. Long-term results of surgical treatment for intrahepatic cholangiocarcinoma according to the tumor mutation status. P.A. Herzen Journal of Oncology. 2021;10(6):6–13. (In Russ.) https://doi.org/10.17116/onkolog2021100616
9. Valle J., Wasan H., Palmer D. H., Cunningham D., Anthoney A., Maraveyas A. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281. https://doi.org/10.1056/NEJMoa0908721
10. Oh D.Y., He A.R., Qin S., Chen L., Okusaka T., Vogel A. et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J Clin Oncol. 2022;40(Suppl. 4):378. https://doi.org/10.1200/JCO.2022.40.4_suppl.378.
11. Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Jun 3;401(10391):1853–1865. doi: 10.1016/S0140–6736(23)00727-4.
12. Savchenko IV, Breder VV, Stilidi IS, Laktionov KK, Kudashkin NE, Egorova AV, Chulkova SV. Second line drug therapy for biliary cancer. Meditsinskiysovet = Medical Council. 2022;(22):136–147. (In Russ.) https://doi.org/10.21518/2079–701X-2022-16-22-136-147
13. Weinberg BA, Xiu J, Lindberg MR, Shields AF, Hwang JJ, Poorman K, Salem ME, Pishvaian MJ, Holcombe RF, Marshall JL, Morse MA. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncology. 2019;10(4):652–662.https://doi.org/10.21037/jgo.2018.08.18
14. Ma B, Meng H, Tian Y, Wang Y, Song T, Zhang T, Wu Q, Cui Y, Li H, Zhang W, Li Q. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma. BMC cancer. 2020;20(1):318.
15. Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, et al. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. CancerDiscov. 2017;7(10):1116–1135. https://doi.org/10.1158/2159–8290.CD-17–0368
16. Walter D, Hartmann S, Waidmann O. Update on cholangiocarcinoma: Potential impact of genomic studies on clinical management. Z Gastroenterol. 2017;55(6):575–581. https://doi.org/10.1055/s-0043–102581
17. Goeppert B, Frauenschuh L, Renner M, et al. BRAF V600E-specifi c immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. ModPathol. 2014;27(7):1028–1034. https://doi.org/10.1038/modpathol.2013.206
18. Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, Yeh TS, Jan YY, Wang HM, Weng JJ, Chang PM, Liu CY, Li CP, Chao Y, Chen MH, Huang CY, Yeh CN. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. Oncotarget. 2014;5(9):2372–2389.https://doi.org/10.18632/oncotarget.1706
19. Javle M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, Zuo M, Barrera C, Alshamsi H, Krishnan S, Mishra L, Wolff RA, Kaseb AO, Thomas MB, Siegel AB. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015;8:58.https://doi.org/10.1186/s13045–015–0155-z
20. Law LY. Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. J ClinOncol. 2012;30(27): e271–273. https://doi.org/10.1200/JCO.2012.42.3061
21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al.; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–1672. https://doi.org/10.1056/NEJMoa052306
22. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al.; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697. https://doi.org/10.1016/s0140–6736(10)61121-x
23. Vtorushin SV, Krakhmal NV, Zavalishina LE, Kuznetsova OA, Moskvina LV, Frank GA. Assessment of HER2 status of carcinomas of various localizations. Russian Journal of Archive of Pathology. 2023;85(6):31–46. (In Russ.) https://doi.org/10.17116/patol20238506131
24. Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profi les: Results From MyPathway, an Open-Label, Phase IIaMultiple Basket Study. J Clin Oncol. 2018;36(6):536–542. https://doi.org/10.1200/JCO.2017.75.3780
25. Javle, M., Borad, M. J., Azad, N. S., Kurzrock, R., Abou-Alfa, G. K., George, B., Hainsworth, J., Meric-Bernstam, F., Swanton, C., Sweeney, C. J., Friedman, C. F., Bose, R., Spigel, D. R., Wang, Y., Levy, J., Schulze, K., Cuchelkar, V., Patel, A., & Burris, H. (2021). Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (My Pathway): a multicentre, open-label, phase 2a, multiple basket study. The Lancet Oncology, 22(9), 1290–1300. https://doi.org/10.1016/S1470–2045(21)00336-3
26. Lee CK, Chon HJ, Cheon J, Lee MA, Im HS, Jang JS, Kim MH, Park S, Kang B, Hong M, Kim JW, Park HS, Kang MJ, Park YN, Choi HJ. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14). Lancet GastroenterolHepatol. 2023 Jan;8(1):56–65. doi: 10.1016/S2468–1253(22)00335-1. Epub 2022 Oct 31.
27. Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022 Jul 7;387(1):9–20. doi: 10.1056/NEJMoa2203690.
28. Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020 Jun 18;382(25):2419–2430. doi: 10.1056/NEJMoa2004413.
29. Bob T Li et al. Trastuzumab deruxtecan in patients with solid tumoursharbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol. 2024 Jun;25(6):707–719. doi: 10.1016/S1470–2045(24)00140-2.
Review
For citations:
Golubev P.V., Kuzmina E.S., Pokataev I.A., Golubeva S.A., Kontorovich D.S., Sydykova R.S., Parts S.A., Galkin V.N. Own experience of using anti-HER2 therapy for cancer of the intrahepatic cholangiocarcinoma. Medical alphabet. 2024;(32):14-18. (In Russ.) https://doi.org/10.33667/2078-5631-2024-32-14-18
Views:
189
Email this article 